primary endpoint

Type: Keyphrase
Name: primary endpoint
First reported 15 hours ago - Updated 53 mins ago - 1 reports

Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation, and Oxidative Stress

Background Recent trials of fish oil for the prevention of atrial fibrillation (AF) recurrence have provided mixed results. Notable uncertainties in the existing evidence base include the roles of high-dose fish oil, inflammation, and oxidative stress ... [Published Journal of the American College of Cardiology - 15 hours ago]
First reported 1 hour ago - Updated 1 hour ago - 2 reports

Sector Update: Health Care Shares Flat in...

PFE: flatABT: flatMRK: flatAMGN: +0.66%Health-care shares were generally flat in pre-market trade Tuesday.In health-care stocks news, Regeneron ( REGN ) and Sanofi ( SNY ) Tuesday reported that the second phase of a proof-of-concept study of investigational ... [Published Nasdaq - 1 hour ago]
Entities: Healthcare, polyp, Stocks
First reported Sep 29 2014 - Updated 2 hours ago - 1 reports

Tonix Pharmaceuticals (TNXP) tumbles as tests fail endpoint.

Tonix Pharmaceuticals Holding (NASDAQ: TNXP) shares slipped 55.4% to $6.23 after the company reported Phase 2b BESTFIT trial of TNX-102 SL in patients with fibromyalgia. The study did not meet primary endpoint. Share volume was 166,000, towering over ... [Published BayStreet.ca - Sep 29 2014]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Tonix Is A Buy On Endpoint Circumstances

By Joe Springer: Tonix Pharmaceuticals (NASDAQ:TNXP) reported BESTFIT results that did not achieve the study's primary endpoint of mean change in pain. The Pain With a p-value of .086 (implying 91.4% certainty) in mean change, the result was near the ... [Published Austin American Statesman - 8 hours ago]
First reported Sep 29 2014 - Updated 18 hours ago - 1 reports

Endologix Sees Higher Q3 Global Revenue; But Cuts FY14 Outlook - Quick Facts

Endologix Inc. (ELGX: Quote) said that it anticipates third quarter 2014 global revenue of about $37.0 million, representing about 11% growth as compared to $33.3 million for the third quarter 2013. Analysts polled by Thomson Reuters expect the company ... [Published RTTNews.com - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Tonix shares battered as lead fibromyalgia drug flops in PhIIb

Shares of Tonix Pharmaceuticals were hammered early Monday after the biotech put out word that its lead drug had failed a Phase IIb study for fibromyalgia.According to Tonix ($TNPX), TNX-102 SL flopped on the primary endpoint: a change in patients' daily ... [Published FierceBiotech - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Morning Market Losers

Tonix Pharmaceuticals Holding (NASDAQ: TNXP) shares dropped 55.09% to $6.27 after the company reported Phase 2b BESTFIT trial of TNX-102 SL in patients with fibromyalgia. The study did not meet primary endpoint.Civeo (NYSE: CVEO) shares declined 41.89% ... [Published Benzinga.com - Sep 29 2014]
Entities: NASDAQ, Market, Mattel Inc
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Boehringer Ingelheim#s afatinib Achieves Primary Endpoint in Global Phase III Study in

REGION WITH FIVE CONSECUTIVE QUARTERS OF MARKET SHARE INCREASES Sun's Unix server market in Thailand achieves 64% market share, 3 times more than the second ranke...NEW TREATMENT... ALDERLEY PARK: A potential new treatment for people suffering from manic ... [Published Newswit.com - Sep 29 2014]
First reported Sep 27 2014 - Updated Sep 28 2014 - 4 reports

SAPA - PR-LUX-LUNG-8-TRIAL

PR-LUX-LUNG-8-TRIALContributed by NAMPA / SAPA.SAPA PR -- LUX-LUNG 8 TRIAL MET IS PRIMARY ENDPOINTIssued by: Business WireAttention: Health EditorsFor immediate release:Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib ... [Published Namibia Press Agency - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 2 reports

Valeant Pharmaceuticals International (VRX) Jumped On Study Results

Valeant Pharmaceuticals International (VRX: Quote) announced Thursday morning that its wholly owned subsidiary, Bausch + Lomb and Nicox S.A. announced that the Phase 3 study of VESNEO met its primary endpoint. VESNEO is used for the reduction of intraocular ... [Published RTTNews.com - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 12 reports

Positive Late-Stage Data Reported for Glaucoma Candidate Vesneo (Latanoprostene Bunod)

FDA submission expected in mid-2015Promising results have been reported from pivotal phase III studies of Vesneo (latanoprostene bunod; Valeant Pharmaceuticals International/Bausch + Lomb/Nicox S.A.) for the reduction of intraocular pressure (IOP) in ... [Published PT Community - Sep 25 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 2 reports

BRIEF-Novartis secukinumab meets primary endpoint in two Phase III studies in psoriatic arthritis

Sept 25 (Reuters) - Novartis AG :* Says AIN457 (secukinumab) is first ever IL-17A inhibitor tomeet primaryendpoint in two Phase III studies in psoriatic arthritis* Says secukinumab met primary and key secondary endpoints intwo pivotal PhaseIII studies ... [Published Reuters UK - Sep 25 2014]

Quotes

...to leverage the broad potential of aldoxorubicin into a variety of solid tumor and hematological indications, " said CytRx CEO Steven A Kriegsman. "We are particularly interested in the potential of aldoxorubin in small cell lung cancer, as this tumor type typically is more sensitive to chemotherapy than STS."
...with nasal polyps also have asthma or atopic dermatitis and vice versa," said Neil Graham, M D , Vice President, Program Management at Regeneron. "The new data reported today, together with prior Phase 2 data with in asthma and atopic dermatitis, support the growing body of scientific evidence that these conditions may result from a core allergic inflammatory process driven by the IL-4/IL-13 pathway."
Shin J Oh, MD, Distinguished Professor Emeritus of Neurology, University of Alabama at Birmingham, School of Medicine, stated, "I am extremely pleased to see the results from the first ever Phase 3 controlled study in this LEMS patient population, which confirmed a positive treatment effect for Firdapse. When combined with the favorable safety profile, the results indicate that the drug should become the standard of care in treating LEMS patients once approved by the FDA."
...require the upmost attention to ensure on-going levels of wellness," said Joe Lynch, Omnicell vice president, marketing - medication adherence. "Dr. Pinto's tireless research has shown that patients want to participate in improving their own lives. We are confident that when the final data are presented, this will be seen as the most comprehensive independent evaluation of how impactful adherence packaging can be in improving patient outcomes."

More Content

All (1267) | News (1076) | Reports (0) | Blogs (164) | Audio/Video (0) | Fact Sheets (1) | Press Releases (15)
sort by: Date | Relevance
CytRx begins aldoxorubicin Phase 2b clinical tr... [Published News-Medical.Net - 1 hour ago]
Sector Update: Health Care Shares Flat in... [Published Nasdaq - 1 hour ago]
Sector Update: Health Care [Published Nasdaq - 1 hour ago]
Sanofi and Regeneron announce positive phase 2 ... [Published Hospital Pharmacy Europe - 4 hours ago]
CytRx Begins Global Phase 2b Trial Of Aldoxorub... [Published RTTNews.com - 4 hours ago]
Janssen, AZ and Roche at ESMO [Published PMLive - 4 hours ago]
ESMO 2014: GSK reports 45% survival rate in Taf... [Published Pharma Letter - 4 hours ago]
PLEGRIDY™ (PEGINTERFERON BETA-1A) TWO-YEAR DATA... [Published MyNewsDesk - 6 hours ago]
Tonix Is A Buy On Endpoint Circumstances [Published Austin American Statesman - 8 hours ago]
Regeneron and Sanofi Announce Positive Phase 2 ... [Published KSFY - 8 hours ago]
Regeneron and Sanofi Announce Positive Phase 2 ... [Published Bio-Medicine - 8 hours ago]
Regeneron, Sanofi Report Positive Phase 2 Dupil... [Published RTTNews.com - 8 hours ago]
Regeneron, Sanofi Report Positive Phase 2 Top-l... [Published RTTNews.com - 9 hours ago]
Regeneron and Sanofi Announce Positive Phase 2 ... [Published Stockwatch - 9 hours ago]
Fish Oil for the Reduction of Atrial Fibrillati... [Published Journal of the American College of Cardiology - 15 hours ago]
Pertuzumab (Perjeta) Regimen Extends Survival i... [Published PT Community - 17 hours ago]
Small Dense Low Density Lipoprotein Particles A... [Published Plosone.org - 17 hours ago]
Endocyte's TARGET Interim Data Positive for Lun... [Published Yahoo! Finance - 17 hours ago]
Endocyte's TARGET Interim Data Positive for Lun... [Published Zacks.com - 17 hours ago]
Catalyst Pharmaceuticals Announces Positive Top... [Published Virtual Strategy Magazine - 18 hours ago]
Closing Update: Hong Kong Protests Trigger Glob... [Published Nasdaq - 18 hours ago]
First Patients Enrolled in Landmark Clinical St... [Published Pharmaceutical & Medical Packaging News - 18 hours ago]
Catalyst Pharmaceuticals Announces Positive Top... [Published SearchBug - 18 hours ago]
Metamark Announces Portfolio Expansion To Inclu... [Published Finwin - 18 hours ago]
Metamark Announces Portfolio Expansion To Inclu... [Published Pettinga Financial Advisors - 18 hours ago]
Metamark Announces Portfolio Expansion To Inclu... [Published BusinessWeek - 18 hours ago]
Acasti Pharma says CaPre drug successfully redu... [Published Proactive Investors USA - 19 hours ago]
Nutritional Advice in Older Patients at Risk of... [Published Plosone.org - 19 hours ago]
Positive Results for Meritage's Budesonide to T... [Published PharmaAsia - 19 hours ago]
Thoratec Announces Start Of Heartmate III U.S. ... [Published Diagnostic & Invasive Cardiology - 19 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Exelixis Announces Positive Results from Phase ... [Published Business Wire Health News - Sep 29 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis Inc. (NASDAQ:EXEL) today announced the positive results from coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator Genentech, a member of the Roche Group, evaluating cobimetinib, a ...
Boehringer Ingelheim’s afatinib Achieves Primar... [Published PRESSEMITTEILUNGEN - Sep 27 2014]
Ingelheim, Germany (ots/PRNewswire) - – Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression ...
Frontrunning: September 25 [Published Zero Hedge - Sep 25 2014]
Apple CEO Cook Goes From Record Sales to IPhone Stumbles ( BBG ) Deal With Saudis Paved Way for Syrian Airstrikes ( WSJ ) Drone delivery: DHL 'parcelcopter' flies to German isle ( Reuters ) Tory Burch Hires Ralph Lauren Veteran as Co-CEO ( WSJ ) Apple ...
Making Sense of Genetic Manuipulation in humans... [Published Multiple Sclerosis Research - Sep 25 2014]
Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; For the ATL1102 Study Group.  CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology. 2014 Sep. pii: 10.1212/WNL.0000000000000926. [Epub ahead of print]OBJECTIVE: This ...
Bausch + Lomb and Nicox's Glaucoma Candidate VE... [Published PR Newswire: Policy & Public Interest - Sep 25 2014]
Expect to file in the U.S. in First Half of Q2 2015 Expect to launch in the U.S. in First Half of 2016Peak U.S. sales ~$500 million+, Peak Global Sales ~$1 billion+LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Sept. 25, 2014 /PRNewswire/ -- Valeant ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
ZS Pharma Announces Positive Top-Line Results F... [Published GlobeNewswire: Advertising News - Sep 23 2014]
DBV Technologies Announces Primary Endpoint Met... [Published GlobeNewswire: Acquisitions News - Sep 22 2014]
Moberg Pharma announces successful results for ... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
NeuroSearch appeals Copenhagen City Court judgm... [Published GlobeNewswire: Acquisitions News - Aug 18 2014]
Sanofi and Regeneron Announce Positive Results ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.